Finding New Drugs That Treat Breast Cancer Is Thought to Be Well Tolerated

This article examines Finding New Drugs That Treat Breast Cancer Is Thought to Be Well Tolerated. It presents the main facts, practical implications, and key points in a clearer, easier-to-follow format.

Understanding Finding New Drugs That Treat Breast Cancer Is Thought to Be Well

Research shows that a new drug has been proven successful in treating the most common forms of breast cancer well tolerated by patients. .

Accordingly, this new oral drug, cyclin-dependent kinase, or CDK inhibitor, has shown great success in the treatment of the most common forms of breast cancer known as metastatic breast cancer. in normal hormones or breast cancer.

The Food and Drug Administrationm, USA recently approved the first CDK palbociclib inhibitor in February 2015 and ribociclib (also known as Kisqali) in March 2017. A third drug, abemacicib, currently are undergoing trials at Stage 3.

Aditya Bardia, a breast cancer specialist at the Massachusetts General Hospital Cancer Center in Boston, said: "CDK inhibitors have changed the system that constitutes HR + breast cancer. ."

CDK inhibitors are very successful in treatment because of the ability to intervene on the nucleus of cancer cells quickly by blocking the activity of harmful enzymes called CDK, especially CDK 4 and CDK 6.

Bardia said: "With the surprising effect of these drugs, there have been numerous clinical trials taking place in patients with metastatic breast cancer. ."

However, unlike some other hormonal therapies, there will be some side effects that occur when taking this medication, which is something we feel is important and there must be a thematic article related to these medications. Potential toxicity and drug interactions with the use of CDK 4/6 inhibitors as well as a synthesis of better practical management strategies for oncologists'.

This research has just been published on the Oncologist page.

In addition, the researchers looked at all studies available on three types of CDK inhibitors and found that the most common side effect was a low white blood cell count, called leukopenia, that could increase the risk. infection. The effect of neutropenia is temporary and depends on the dose used.

Neutropenia is less common with abemaciclib, but causes more common side effects such as diarrhea and fatigue. Nausea and hair loss are less common side effects that researchers have found.